Protara Therapeutics, Inc. (TARA)
2.70
-0.06
(-2.17%)
USD |
NASDAQ |
Oct 02, 16:00
2.695
0.00 (0.00%)
After-Hours: 20:00
Protara Therapeutics EPS Diluted (Quarterly) : -0.3552 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.3552 |
| March 31, 2026 | -0.309 |
| December 31, 2025 | -0.3759 |
| September 30, 2025 | -0.3136 |
| June 30, 2025 | -0.3539 |
| March 31, 2025 | -0.2927 |
| December 31, 2024 | -0.4831 |
| September 30, 2024 | -0.5024 |
| June 30, 2024 | -0.448 |
| March 31, 2024 | -0.9715 |
| December 31, 2023 | -0.8994 |
| September 30, 2023 | -0.8689 |
| June 30, 2023 | -0.9988 |
| March 31, 2023 | -0.8002 |
| December 31, 2022 | -3.458 |
| September 30, 2022 | -0.6827 |
| June 30, 2022 | -0.7587 |
| March 31, 2022 | -0.956 |
| December 31, 2021 | -0.9103 |
| September 30, 2021 | -0.9592 |
| June 30, 2021 | -1.132 |
| March 31, 2021 | -1.199 |
| December 31, 2020 | -0.7882 |
| September 30, 2020 | -1.260 |
| June 30, 2020 | -1.222 |
| Date | Value |
|---|---|
| March 31, 2020 | -1.809 |
| December 31, 2019 | -38.35 |
| September 30, 2019 | -36.72 |
| June 30, 2019 | -22.34 |
| March 31, 2019 | -23.26 |
| December 31, 2018 | -10.94 |
| September 30, 2018 | -10.12 |
| June 30, 2018 | -11.04 |
| March 31, 2018 | -13.76 |
| December 31, 2017 | -12.60 |
| September 30, 2017 | -43.20 |
| June 30, 2017 | -13.20 |
| March 31, 2017 | -15.60 |
| December 31, 2016 | -16.80 |
| September 30, 2016 | -17.20 |
| June 30, 2016 | -19.20 |
| March 31, 2016 | -16.00 |
| December 31, 2015 | -15.20 |
| September 30, 2015 | -13.20 |
| June 30, 2015 | -12.40 |
| March 31, 2015 | -11.20 |
| December 31, 2014 | 21.36 |
| September 30, 2014 | -19.90 |
| June 30, 2014 | -11.90 |
| March 31, 2014 | -11.59 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| NovelStem International Corp. | -0.0017 |
| Brainstorm Cell Therapeutics, Inc. | -0.3494 |
| Summit Therapeutics, Inc. | -0.2772 |
| Kezar Life Sciences, Inc. | -0.7838 |
| Clene, Inc. | -1.084 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -21.67M |
| Total Expenses (Quarterly) | 21.67M |
| Enterprise Value | 19.78M |
| Earnings Yield | -50.14% |
| Normalized Earnings Yield | -50.14 |